Obsessive-compulsive disorder-related disorders: The role of selective serotonergic reuptake inhibitors

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Obsessive-compulsive spectrum disorders comprise a unique category of related disorders with important diagnostic, aetiological and therapeutic implications. This group of disorders may overlap with obsessive-compulsive disorder (OCD) in symptomatic profile, demographics, family history, neurobiology, comorbidity, clinical course and response to selective anti-obsessional behavioural and pharmacotherapies. OCD-related disorders can be viewed along a continuum with risk avoidance on the compulsive end and risk seeking at the other. This dimension may be defined within a framework which relates hyperfrontality and increased serotonergic sensitivity with compulsive disorders and hyperfrontality and low presynaptic serotonergic levels with impulsive disorders. Most biological models of OCD-related disorders stress the importance of serotonin in their pathophysiology and these disorders have also been shown to be preferentially responsive to selective serotonergic reuptake inhibitors (SSRIs). This paper reviews the management of the OCD spectrum and the evidence for efficacy of the SSRIs and the differential treatment responses of the compulsive and impulsive disorders with regard to therapeutic dosage, response lag time and maintenance of symptom remission.

Original languageEnglish (US)
Pages (from-to)75-87
Number of pages13
JournalInternational Clinical Psychopharmacology
Volume11
Issue numberSUPPL. 5
StatePublished - 1996
Externally publishedYes

Fingerprint

Obsessive-Compulsive Disorder
Biological Models
Neurobiology
Comorbidity
Serotonin
Therapeutics
Maintenance
Demography
Drug Therapy

Keywords

  • clinical trials
  • disease management
  • fluoxetine
  • fluvoxamine
  • obsessive-compulsive disorder
  • obsessive-compulsive-related disorders-SSRIs
  • sertraline

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology (medical)
  • Neuroscience(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

@article{be514fde4a79454fb7e2242a027e0023,
title = "Obsessive-compulsive disorder-related disorders: The role of selective serotonergic reuptake inhibitors",
abstract = "Obsessive-compulsive spectrum disorders comprise a unique category of related disorders with important diagnostic, aetiological and therapeutic implications. This group of disorders may overlap with obsessive-compulsive disorder (OCD) in symptomatic profile, demographics, family history, neurobiology, comorbidity, clinical course and response to selective anti-obsessional behavioural and pharmacotherapies. OCD-related disorders can be viewed along a continuum with risk avoidance on the compulsive end and risk seeking at the other. This dimension may be defined within a framework which relates hyperfrontality and increased serotonergic sensitivity with compulsive disorders and hyperfrontality and low presynaptic serotonergic levels with impulsive disorders. Most biological models of OCD-related disorders stress the importance of serotonin in their pathophysiology and these disorders have also been shown to be preferentially responsive to selective serotonergic reuptake inhibitors (SSRIs). This paper reviews the management of the OCD spectrum and the evidence for efficacy of the SSRIs and the differential treatment responses of the compulsive and impulsive disorders with regard to therapeutic dosage, response lag time and maintenance of symptom remission.",
keywords = "clinical trials, disease management, fluoxetine, fluvoxamine, obsessive-compulsive disorder, obsessive-compulsive-related disorders-SSRIs, sertraline",
author = "Eric Hollander",
year = "1996",
language = "English (US)",
volume = "11",
pages = "75--87",
journal = "International Clinical Psychopharmacology",
issn = "0268-1315",
publisher = "Lippincott Williams and Wilkins",
number = "SUPPL. 5",

}

TY - JOUR

T1 - Obsessive-compulsive disorder-related disorders

T2 - The role of selective serotonergic reuptake inhibitors

AU - Hollander, Eric

PY - 1996

Y1 - 1996

N2 - Obsessive-compulsive spectrum disorders comprise a unique category of related disorders with important diagnostic, aetiological and therapeutic implications. This group of disorders may overlap with obsessive-compulsive disorder (OCD) in symptomatic profile, demographics, family history, neurobiology, comorbidity, clinical course and response to selective anti-obsessional behavioural and pharmacotherapies. OCD-related disorders can be viewed along a continuum with risk avoidance on the compulsive end and risk seeking at the other. This dimension may be defined within a framework which relates hyperfrontality and increased serotonergic sensitivity with compulsive disorders and hyperfrontality and low presynaptic serotonergic levels with impulsive disorders. Most biological models of OCD-related disorders stress the importance of serotonin in their pathophysiology and these disorders have also been shown to be preferentially responsive to selective serotonergic reuptake inhibitors (SSRIs). This paper reviews the management of the OCD spectrum and the evidence for efficacy of the SSRIs and the differential treatment responses of the compulsive and impulsive disorders with regard to therapeutic dosage, response lag time and maintenance of symptom remission.

AB - Obsessive-compulsive spectrum disorders comprise a unique category of related disorders with important diagnostic, aetiological and therapeutic implications. This group of disorders may overlap with obsessive-compulsive disorder (OCD) in symptomatic profile, demographics, family history, neurobiology, comorbidity, clinical course and response to selective anti-obsessional behavioural and pharmacotherapies. OCD-related disorders can be viewed along a continuum with risk avoidance on the compulsive end and risk seeking at the other. This dimension may be defined within a framework which relates hyperfrontality and increased serotonergic sensitivity with compulsive disorders and hyperfrontality and low presynaptic serotonergic levels with impulsive disorders. Most biological models of OCD-related disorders stress the importance of serotonin in their pathophysiology and these disorders have also been shown to be preferentially responsive to selective serotonergic reuptake inhibitors (SSRIs). This paper reviews the management of the OCD spectrum and the evidence for efficacy of the SSRIs and the differential treatment responses of the compulsive and impulsive disorders with regard to therapeutic dosage, response lag time and maintenance of symptom remission.

KW - clinical trials

KW - disease management

KW - fluoxetine

KW - fluvoxamine

KW - obsessive-compulsive disorder

KW - obsessive-compulsive-related disorders-SSRIs

KW - sertraline

UR - http://www.scopus.com/inward/record.url?scp=0030448249&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030448249&partnerID=8YFLogxK

M3 - Article

C2 - 9032004

AN - SCOPUS:0030448249

VL - 11

SP - 75

EP - 87

JO - International Clinical Psychopharmacology

JF - International Clinical Psychopharmacology

SN - 0268-1315

IS - SUPPL. 5

ER -